Valuation: Bolt Biotherapeutics, Inc.

Market Cap 7.5M 6.57M 6.07M 5.66M 10.66M 709M 10.91M 72.99M 28.18M 350M 28.18M 27.56M 1.22B P/E 2026 *
-0.02x
P/E 2027 * -0.02x
Enterprise Value 7.5M 6.57M 6.07M 5.66M 10.66M 709M 10.91M 72.99M 28.18M 350M 28.18M 27.56M 1.22B EV / Sales 2026 *
4.97x
EV / Sales 2027 * 2.14x
Free-Float
96.53%
Yield 2026 *
-
Yield 2027 * -
1 day-8.66%
1 week-2.62%
Current month-25.62%
1 month-25.62%
3 months-10.84%
6 months-27.42%
Current year-28.58%
1 week 3.9
Extreme 3.9
4.41
1 month 3.75
Extreme 3.75
5.7
Current year 3.75
Extreme 3.75
7.2
1 year 3.75
Extreme 3.75
7.2
3 years 3.75
Extreme 3.75
31.2
5 years 3.75
Extreme 3.75
385.7
10 years 3.75
Extreme 3.75
861.4
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 2024-05-14
Chief Executive Officer 54 2024-05-14
Chief Operating Officer 61 2024-05-14
Director TitleAgeSince
Director/Board Member 64 2020-11-30
Director/Board Member 54 2024-05-14
Chairman 55 2024-09-03
Date Insider Type Main position Quantity % Market Cap.
06-09Free

Director

5,000 0.2602%
06-09Free

Chairman

5,000 0.2602%
06-09Free

Director

5,000 0.2602%
Change 5-day change 1-year change 3-year change Capi.($)
-8.66%-2.62%-30.39%-85.32% 8.21M
+0.13%-1.33%+63.86%+121.93% 55.63B
+6.76%+22.83%+91.66%+101.42% 52.25B
+3.33%+4.51%-11.68%-11.91% 23.07B
+1.32%+6.22%+5.28%+415.45% 22.41B
+6.78%+14.47%+40.28%-6.67% 17.32B
+0.97%+5.01%+31.23%-32.10% 15.94B
-0.89%+5.71%+24.30%+186.29% 13.77B
+9.96%+19.81%+157.65%+320.70% 13.47B
+4.21%+4.76%+33.21% - 12.43B
Average +2.39%+6.87%+40.54%+112.20% 22.63B
Weighted average by Cap. +3.42%+7.62%+54.16%+127.99%

Financials

2026 *2027 *
Net sales 1.51M 1.32M 1.22M 1.14M 2.14M 143M 2.19M 14.68M 5.67M 70.37M 5.67M 5.54M 244M 3.5M 3.06M 2.83M 2.64M 4.97M 331M 5.09M 34.05M 13.14M 163M 13.14M 12.86M 567M
Net income -44.52M -38.98M -35.99M -33.61M -63.26M -4.21B -64.7M -433M -167M -2.08B -167M -164M -7.21B -47.5M -41.59M -38.4M -35.85M -67.49M -4.49B -69.03M -462M -178M -2.22B -178M -174M -7.69B
Net Debt - -
Logo Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing immunotherapies for the treatment of cancer. The Company’s pipeline includes BDC-3042, an agonist antibody that activates macrophages by targeting dectin-2, and BDC-4182, a next generation Boltbody Immune-Stimulating Antibody Conjugate (ISAC) clinical candidate targeting claudin 18.2. BDC-3042 is in a Phase I dose escalation trial that includes patients with any of seven different solid tumor types. The Company’s Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. It has two additional ISAC programs utilizing its Boltbody ISAC technology platform in preclinical development. One is a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 (CEA). Its final Boltbody ISAC program targets PD-L1. The Company is also developing additional Boltbody ISACs in strategic collaborations with biopharmaceutical companies.
Employees
23
Date Price Change Volume
26-06-29 US$3.905 -8.66% 79,091
26-06-26 US$4.275 +1.79% 12,146
26-06-25 US$4.200 -0.47% 8,958
26-06-24 US$4.220 -1.06% 6,775
26-06-23 US$4.265 +6.36% 28,400
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
3.905USD
Average target price
41.00USD
Spread / Average Target
+949.94%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BOLT Stock